Although this study did not specifically focus on CKD, it underscores the importance of individualized antiplatelet strategies in Asian patients and suggests that more potent P2Y12 inhibitors may not uniformly provide net benefit in these populations. The gene discussed is P2RY12; the disease is chronic kidney disease.